ORCHID PHARMA LIMITED Environmental Analytics
Environmental and financial analysis dashboard for ORCHID PHARMA LIMITED. Industry: MANUFACTURING
Company Overview for ORCHID PHARMA LIMITED
Highlights
Showing data for FY2022
Operational Environmental Cost
$86m
Operational Environmental Cost Intensity
106%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
N/A
Decoupling Rate (2020-2022)
N/A
Adjusted EBITDA
$-77m
Adjusted EBITDA Margin
-95%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| N/A | 19.75% | -92.17% | ||
| N/A | 1.16% | 1.26% | 0.08% | |
| N/A | -6.25% | -88.46% | ||
| N/A | 122.74% | 104.86% | 9.98% | |
| N/A | $91m | $86m | $10m | |
| N/A | -6.00% | -88.50% | ||
| N/A | 123.90% | 106.13% | 10.06% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-95%
Adjusted EBIT Margin
-111%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$62m | $74m | $81m | $98m | |
| 19.95% | 9.74% | 21.24% | ||
N/A | $63m | $72m | $77m | |
| 0.00% | 85.56% | 88.90% | 78.64% | |
N/A | $11m | $9m | $21m | |
| 0.00% | 14.44% | 11.10% | 21.36% | |
N/A | $-7m | $-4m | $13m | |
| 0.00% | -9.76% | -4.45% | 13.14% | |
| ENVIRONMENTAL COST DATA | ||||
N/A | $91m | $86m | $10m | |
| 0.00% | 123.90% | 106.13% | 10.06% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
N/A | $-81m | $-77m | $11m | |
| 0.00% | -109.46% | -95.02% | 11.30% | |
N/A | $-99m | $-90m | $3m | |
| 0.00% | -133.66% | -110.57% | 3.07% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
1.26%
Scope 2 (% of Sales)
105%
Operational Environmental Cost Intensity
106%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
ORCHID PHARMA LIMITED | IN | $86m | 106.13% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022